Quest Diagnostics (DGX) Capital Expenditures (2009 - 2026)

Quest Diagnostics has disclosed Capital Expenditures across 18 years of filings, most recently posting $114.0 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $114.0 million, down 2.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $524.0 million (up 19.63% YoY), and the FY2025 annual result was $527.0 million, up 24.0% from the prior year.
• Capital Expenditures came in at $114.0 million for Q1 2026 at Quest Diagnostics, down from $158.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $158.0 million in Q4 2025 to a low of $63.0 million in Q1 2022.
• The 5-year median for Capital Expenditures is $108.0 million (2025), against an average of $110.5 million.
• Peak annual rise in Capital Expenditures reached 101.59% in 2023, while the deepest fall reached 51.02% in 2023.
• Quest Diagnostics' Capital Expenditures stood at $147.0 million in 2022, then plunged by 51.02% to $72.0 million in 2023, then surged by 70.83% to $123.0 million in 2024, then increased by 28.46% to $158.0 million in 2025, then declined by 27.85% to $114.0 million in 2026.
• The last three Capital Expenditures figures came in at $114.0 million (Q1 2026), $158.0 million (Q4 2025), and $144.0 million (Q3 2025), per Business Quant data.